Aurora Improves Offerings in Australia with New Range of Premium Dried Flower Products
Rhea-AI Summary
Aurora Cannabis Inc. (ACB) and MedReleaf Australia have expanded their product offerings in Australia by introducing a new line of premium dried cannabis flower products. These products, including proprietary cultivars like Black Jelly, Chemango Kush, and Moon Berry, aim to provide patients with more choice and high-quality medical cannabis solutions. The expansion also includes the relaunch of the Vespera cultivar under the Aurora brand. The products are distributed by MedReleaf Australia, positioning itself as a leading distributor in the Australian market.
Positive
Introduction of new premium dried cannabis flower products to cater to the growing market demand in Australia.
Expansion of Aurora's product portfolio in Australia through innovative and proprietary cultivars like Black Jelly, Chemango Kush, and Moon Berry.
Relaunch of the Vespera cultivar under the Aurora brand, offering patients more options for medical cannabis treatment.
Focus on sustainability with 2.0 genetics employed in cultivars for reliable large-scale cultivation while maintaining high quality standards.
Negative
- None.
News Market Reaction – ACB
In the trading session that priced this news, ACB gained 46.04%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASDAQ | TSX: ACB
The new dried flowers, including Black Jelly, Chemango Kush, and Moon Berry, are proprietary cultivars cultivated exclusively by Aurora. Vespera, a previously existing proprietary cultivar, is also set for relaunch under the Aurora brand. These products mark a significant step forward for MedReleaf Australia as they continue to expand their offerings under the Aurora brand. The dried flower products are available now in four 10g formats including:
- Aurora Moon Berry T9/C13 Balanced
- Aurora Black Jelly T28/C1 Sativa
- Aurora Chemango Kush T29/C1 Indica
- Aurora Vespera T1/C17 CBD
"This expanded offering aims to serve patients with more choice, novel cultivars and expertly grown product," said Kristin Viccars, Managing Director at MedReleaf Australia. "With the launch of the new Aurora dried flower products, MedReleaf Australia reaffirms its commitment to providing high-quality medical cannabis solutions that meet the diverse needs of patients across
The expanded range of Aurora products caters to the market demand for more affordable options without compromising on quality. With a focus on sustainability, the 2.0 genetics employed in these cultivars ensure reliable large-scale cultivation to meet market demand while maintaining elevated quality standards.
Furthermore, the MedReleaf Australia family of brands now focuses on three core brands - CraftPlant, offering a hand-crafted, premium range of products; Aurora, for innovative and affordable options; and IndiMed, providing a company-funded concession range.
For additional information doctors and health care professionals can contact MedReleaf Australia's clinical support team or visit their website: www.medreleafaustralia.com.au.
Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton,
Aurora's Common Shares trade on the NASDAQ and TSX under the symbol "ACB".
MedReleaf Australia is a subsidiary company of Aurora Cannabis Inc., established in 2016 and acquired in 2024. MedReleaf is licensed by the Australian Federal Government's Office of Drug Control (ODC) to cultivate and manufacture medical cannabis. MedReleaf also has licenses to import, export and wholesale medical cannabis. Its wholly owned subsidiary in
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the continued expansion of the Company's productportfolio in
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-improves-offerings-in-australia-with-new-range-of-premium-dried-flower-products-302131189.html
SOURCE Aurora Cannabis Inc.
FAQ
What new products have Aurora Cannabis Inc. and MedReleaf Australia introduced in Australia?
Aurora Cannabis Inc. and MedReleaf Australia have introduced a new range of premium dried cannabis flower products in Australia.
Who will distribute the new dried flower products in Australia?
The new dried flower products will be distributed by MedReleaf Australia, a premier distributor of medical cannabis products in Australia.
Where can doctors and health care professionals find more information about the new products?
Doctors and health care professionals can contact MedReleaf Australia's clinical support team or visit their website at www.medreleafaustralia.com.au for additional information about the new products.